News
SNY
47.73
-0.93%
-0.45
Aventis Energy files NI 43-101 technical report for Sting Copper project in Newfoundland and Labrador
Reuters · 14h ago
Sanofi (SNYNF) Gets a Hold from Kepler Capital
TipRanks · 1d ago
Sanofi Builds Immunology Momentum with March 2026 Wave of Global Approvals and Data
TipRanks · 1d ago
Is Trump to blame for delayed drug launches in Europe
Seeking Alpha · 1d ago
Trump Trade: U.S. not pulling assets from Strait of Hormuz yet
TipRanks · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)
TipRanks · 1d ago
Drugmakers delay drug launch in Europe over U.S. pricing policies, Reuters says
TipRanks · 1d ago
Sanofi Receives EU Conditional Marketing Authorization For Rezurock In Chronic GVHD
NASDAQ · 1d ago
Sanofi: European Commission Grants Conditional Marketing Authorisation For Rezurock
NASDAQ · 1d ago
Sanofi says EU approves Rezurock for chronic graft-versus-host disease treatment
Reuters · 1d ago
Transcenta appoints Christopher Hwang head of global partnerships for HiCB platform
Reuters · 2d ago
Sanofi unveils late-breaking phase 3 amlitelimab data in atopic dermatitis
Seeking Alpha · 2d ago
Biotech Stocks Facing FDA Decision In April 2026
NASDAQ · 2d ago
Weekly Report: what happened at SNY last week (0323-0327)?
Weekly Report · 2d ago
Reported Saturday, Sanofi's Phase 3 COAST And SHORE Data Show Amlitelimab Achieves Up To 48.1% EASI-75 Response With Consistent Safety Profile In 1,833 Atopic Dermatitis Patients
Benzinga · 2d ago
J.P. Morgan Sticks to Their Hold Rating for Sanofi (SNYNF)
TipRanks · 2d ago
Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis
NASDAQ · 4d ago
Sanofi says phase 3 studies show amlitelimab improves atopic dermatitis at Week 24
Reuters · 4d ago
Top Research Reports for Palantir, Linde and Arista Networks
NASDAQ · 5d ago
Former CDC advisor says White House pulling back on vaccine policy
Seeking Alpha · 5d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.